ESTRO 2025 - Abstract Book

S967

Clinical – Head & neck

ESTRO 2025

LLF occurred in 3 patients (41-59-101 months) in A-DPBN and in 2 patients (45-50 months) in S-IMRT. LRF occurred in 1 patient in A-DPBN at 60 months. LDM occurred in 2 S-IMRT patients (at 62-75 months). No LDM was observed in A-DPBN. Five-year OS was 67% and 52% ( p =0.15) and DFS was 59% and 41% ( p =0.13) in A-DPBN and S-IMRT, respectively. No new grade≥3 late toxicity was observed. Conclusion: In contrast to previous publication 1 , there still is a numerically better LC (actuarially 82% vs. 65% at 5 years, respectively) in A-DPBN compared to S-IMRT, but not with the previously statistically significant difference observed after shorter follow-up. No DM >36 months was observed in A-DPBN. No new grade≥3 late toxicity was observed.

Keywords: dose painting by numbers, randomized trial